Skip to main
PASG
PASG logo

PASSAGE BIO (PASG) Stock Forecast & Price Target

PASSAGE BIO (PASG) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Passage Bio Inc is positioned positively due to its strategic amendments in the trial protocols that may allow for earlier intervention in neurodegenerative diseases, potentially enhancing the therapeutic benefits of its product PBFT02. The June 2025 interim data reinforces the robustness of PBFT02, showcasing sustained increases in crucial biomarkers such as CSF PGRN and plasma NfL, which are indicative of treatment efficacy and disease progression slowing. Furthermore, the possibility of regulatory alignment for accelerated approval based solely on biomarker endpoints could facilitate shorter trial timelines, thereby expediting the path to market and enhancing the company’s competitive edge in the genetic medicines sector.

Bears say

The analysis indicates a negative outlook on Passage Bio's stock primarily due to the inherent clinical risks associated with its gene therapy programs, which include potential delays in timelines and the emergence of safety concerns that could adversely affect market sentiment. Additionally, the company faces significant regulatory risks, as success in its clinical development of PBGM01 and PBFT02 may hinge upon the ability to navigate unforeseen safety issues or achieve anticipated efficacy levels. Furthermore, Passage Bio's operational outlook could be constrained if it and its partners fail to establish adequate manufacturing capacity, compounding the financial uncertainties surrounding its pipeline products designed to address rare, monogenic CNS disorders.

PASSAGE BIO (PASG) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PASSAGE BIO (PASG) Forecast

Analysts have given PASSAGE BIO (PASG) a Strong Buy based on their latest research and market trends.

According to 4 analysts, PASSAGE BIO (PASG) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PASSAGE BIO (PASG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.